Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2020

Open Access 01-12-2020 | Insulins | Review

Is insulin-like growth factor-1 involved in Parkinson’s disease development?

Authors: Inma Castilla-Cortázar, Gabriel A. Aguirre, Giovana Femat-Roldán, Irene Martín-Estal, Luis Espinosa

Published in: Journal of Translational Medicine | Issue 1/2020

Login to get access

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder that results in the death of dopaminergic neurons within the substantia nigra pars compacta and the reduction in dopaminergic control over striatal output neurons, leading to a movement disorder most commonly characterized by akinesia or bradykinesia, rigidity and tremor. Also, PD is less frequently depicted by sensory symptoms (pain and tingling), hyposmia, sleep alterations, depression and anxiety, and abnormal executive and working memory related functions. On the other hand, insulin-like growth factor 1 (IGF-1) is an endocrine, paracrine and autocrine hormone with several functions including tissue growth and development, insulin-like activity, proliferation, pro-survival, anti-aging, antioxidant and neuroprotection, among others. Herein this review tries to summarize all experimental and clinical data to understand the pathophysiology and development of PD, as well as its clear association with IGF-1, supported by several lines of evidence: (1) IGF-1 decreases with age, while aging is the major risk for PD establishment and development; (2) numerous basic and translational data have appointed direct protective and homeostasis IGF-1 roles in all brain cells; (3) estrogens seem to confer women strong protection to PD via IGF-1; and (4) clinical correlations in PD cohorts have confirmed elevated IGF-1 levels at the onset of the disease, suggesting an ongoing compensatory or “fight-to-injury” mechanism.
Literature
1.
2.
Erkkinen MG, Kim M-O, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10(4):a033118.PubMedCrossRefPubMedCentral
3.
GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53.CrossRef
4.
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.PubMedCrossRef
5.
Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8(12):1128–39.PubMedCrossRef
6.
7.
8.
9.
Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, et al. Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol. 2013;12(5):514–24.PubMedCrossRef
10.
11.
Juri C, Rodríguez-Oroz MC, Burguera JA, Guridi J, Obeso JA. Pain and dyskinesia in Parkinson’s disease. Mov Disord. 2010;25(1):130–2.PubMedCrossRef
12.
Sabatini U, Boulanouar K, Fabre N, Martin F, Carel C, Colonnese C, et al. Cortical motor reorganization in akinetic patients with Parkinson’s disease: a functional MRI study. Brain. 2000;123(Pt 2):394–403.PubMedCrossRef
13.
Olanow CW. The pathogenesis of cell death in Parkinson’s disease—2007. Mov Disord. 2007;22(SUPPL. 17):S335–42.PubMedCrossRef
14.
Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318(1):121–34.PubMedCrossRef
15.
Mink JW, Blumenschine RJ, Adams DB. Ratio of central nervous system to body metabolism in vertebrates: its constancy and functional basis. Am J Physiol. 1981;241(3):R203–12.PubMed
16.
Connor JR, Benkovic SA. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann Neurol. 1992;32(Suppl):S51–61.PubMedCrossRef
17.
Mills E, Dong X-P, Wang F, Xu H. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem. 2010;2(1):51–64.PubMedCrossRef
18.
Patel NK, Pavese N, Javed S, Hotton GR, Brooks DJ, Gill SS. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology. 2013;81(13):1176–8.PubMedPubMedCentralCrossRef
19.
Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. Neuroreport. 1999;10(3):557–61.PubMedCrossRef
20.
Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.PubMedCrossRef
21.
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292–300.PubMedCrossRef
22.
Van Den Eeden SK. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–22.CrossRef
23.
Rodríguez-Violante M, Villar-Velarde A, Valencia-Ramos C, Cervantes-Arriaga A. Características epidemiológicas de pacientes con enfermedad de Parkinson Arch Neurocien (Mex) INNN. Arch Neurocien. 2011;16:64–8.
24.
25.
Song Y, Gu Z, An J, Chan P. Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson’s disease. Neurol Sci. 2014;35(12):1991–6.PubMedCrossRef
26.
Yamawaki M, Kusumi M, Kowa H, Nakashima K. Changes in prevalence and incidence of Parkinson’s disease in Japan during a quarter of a century. Neuroepidemiology. 2009;32(4):263–9.PubMedCrossRef
27.
28.
Alves G, Müller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, et al. Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2009;80(8):851–7.PubMedCrossRef
29.
Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology. 1997;138(3):863–70.PubMedCrossRef
30.
31.
32.
Vermeulen A, Kaufman JM, Goemaere S, Van Pottelberg I. Estradiol in elderly men. Aging Male. 2002;5(2):98–102.PubMedCrossRef
33.
34.
Gaignard P, Liere P, Thérond P, Schumacher M, Slama A, Guennoun R. Role of sex hormones on brain mitochondrial function, with special reference to aging and neurodegenerative diseases. Front Aging Neurosci. 2017;9:406.PubMedPubMedCentralCrossRef
35.
Mcmahon T, Van Zijl PCM, Gilad AA. NIH Public Access. 2015;27(3):320–31.
36.
González C, Díaz F, Alonso A. Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling. Infect Disord Drug Targets. 2008;8(1):65–7.PubMedCrossRef
37.
38.
Labandeira-Garcia JL, Rodriguez-Perez AI, Valenzuela R, Costa-Besada MA, Guerra MJ. Menopause and Parkinson’s disease. Interaction between estrogens and brain renin–angiotensin system in dopaminergic degeneration. Front Neuroendocrinol. 2016;2016(43):44–59.CrossRef
39.
Haaxma CA, Bloem BR, Borm GF, Oyen WJG, Leenders KL, Eshuis S, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–24.PubMedCrossRef
40.
Hirohata M, Ono K, Morinaga A, Ikeda T, Yamada M. Anti-aggregation and fibril-destabilizing effects of sex hormones on α-synuclein fibrils in vitro. Exp Neurol. 2009;217(2):434–9.PubMedCrossRef
41.
42.
43.
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s Disease. N Engl J Med. 2003;348:1356–64.PubMedCrossRef
44.
45.
46.
Von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473–90.CrossRef
47.
Picillo M, Nicoletti A, Fetoni V, Garavaglia B, Barone P, Pellecchia MT. The relevance of gender in Parkinson’s disease: a review. J Neurol. 2017;264(8):1583–607.PubMedCrossRef
48.
Smith KM, Dahodwala N. Sex differences in Parkinson’s disease and other movement disorders. Exp Neurol. 2014;259:44–56.PubMedCrossRef
49.
Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997;336(9):633–40.PubMedCrossRef
50.
Martín-Estal I, De la Garza R, Castilla-Cortazar I. Intrauterine Growth Retardation (IUGR) as a novel condition deficiency of Insulin-like growth. Retard Intrauter Growth. 2015;1(1):1.
51.
D’Ercole AJ, Applewhite GT, Underwood LE. Evidence that somatomedin is synthesized by multiple tissues in the fetus. Dev Biol. 1980;75:315–28.PubMedCrossRef
52.
53.
Martín-Estal I, de la Garza RG, Castilla-Cortázar I. Intrauterine growth retardation (IUGR) as a novel condition of insulin-like growth factor-1 (IGF-1) deficiency. Rev Physiol Biochem Pharmacol. 2016;4(170):1–35.
54.
Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016;14(1):3.PubMedPubMedCentralCrossRef
55.
Bondy CA, Lee WH. Patterns of insulin-like growth factor and IGF receptor gene expression in the brain. Functional implications. Ann N Y Acad Sci. 1993;692:33–43.PubMedCrossRef
56.
Bach MA, Shen-Orr Z, Lowe WL, Roberts CT, LeRoith D. Insulin-like growth factor I mRNA levels are developmentally regulated in specific regions of the rat brain. Brain Res Mol Brain Res. 1991;10(1):43–8.PubMedCrossRef
57.
Popken GJ, Dechert-Zeger M, Ye P, D’Ercole AJ. Brain development. Adv Exp Med Biol. 2005;567:187–220.PubMedCrossRef
58.
Baron-Van Evercooren A, Olichon-Berthe C, Kowalski A, Visciano G, Van Obberghen E. Expression of IGF-I and insulin receptor genes in the rat central nervous system: a developmental, regional, and cellular analysis. J Neurosci Res. 1991;28(2):244–53.PubMedCrossRef
59.
Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994;135(5):1753–61.PubMedCrossRef
60.
Gong X, Ma M, Fan X, Li M, Liu Q, Liu X, et al. Down-regulation of IGF-1/IGF-1R in hippocampus of rats with vascular dementia. Neurosci Lett. 2012;513(1):20–4.PubMedCrossRef
61.
Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev. 2005;4(2):195–212.PubMedCrossRef
62.
Adem A, Jossan SS, D’Argy R, Gillberg PG, Nordberg A, Winblad B, et al. Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization. Brain Res. 1989;503(2):299–303.PubMedCrossRef
63.
64.
Tong M, Dong M, de la Monte SM. Brain insulin-like growth factor and neurotrophin resistance in Parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis. 2009;16(3):585–99.PubMedPubMedCentralCrossRef
65.
66.
Morris JK, Zhang H, Gupte AA, Bomhoff GL, Stanford JA, Geiger PC. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson’s disease. Brain Res. 2008;1240:185–95.PubMedPubMedCentralCrossRef
67.
Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig. 2012;122(4):1316–38.PubMedCrossRefPubMedCentral
68.
Fernandez AM, Torres-Alemán I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012;13(4):225–39.PubMedCrossRef
69.
Bäckström M, Hall K, Sara V. Somatomedin levels in cerebrospinal fluid from adults with pituitary disorders. Acta Endocrinol. 1984;107(2):171–8.CrossRef
70.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002;8:1390–7.PubMedCrossRef
71.
Kalmar B, Greensmith L. Induction of heat shock proteins for protection against oxidative stress. Adv Drug Deliv Rev. 2009;61(4):310–8.PubMedCrossRef
72.
Garcia-Fernandez M, Sierra I, Puche JE, Guerra L, Castilla-Cortazar I. Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats. J Transl Med. 2011;9:123.PubMedPubMedCentralCrossRef
73.
Castilla-Cortázar I, García-Fernández M, Delgado G, Puche JE, Sierra I, Barhoum R, et al. Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats. J Transl Med. 2011;9:103.PubMedPubMedCentralCrossRef
74.
Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988;37(2):136–40.PubMedCrossRef
75.
Dyer AH, Vahdatpour C, Sanfeliu A, Tropea D. The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticity. Neuroscience. 2016;325:89–99.PubMedCrossRef
76.
77.
Ye P, Li L, Richards RG, DiAugustine RP, D’Ercole AJ. Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci. 2002;22(14):6041–51.PubMedPubMedCentralCrossRef
78.
Popken GJ, Hodge RD, Ye P, Zhang J, Ng W, O’Kusky JR, et al. In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central nervous system. Eur J Neurosci. 2004;19(8):2056–68.PubMedCrossRef
79.
Ye P, D’Ercole AJ. Insulin-like growth factor actions during development of neural stem cells and progenitors in the central nervous system. J Neurosci Res. 2006;83(1):1–6.PubMedCrossRef
80.
81.
Huat TJ, Khan AA, Pati S, Mustafa Z, Abdullah JM, Jaafar H. IGF-1 enhances cell proliferation and survival during early differentiation of mesenchymal stem cells to neural progenitor-like cells. BMC Neurosci. 2014;15:91.PubMedPubMedCentralCrossRef
82.
Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Sci World J. 2006;6:53–80.CrossRef
83.
O’Kusky JR, Ye P, D’Ercole AJ. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J Neurosci. 2000;20(22):8435–42.PubMedPubMedCentralCrossRef
84.
Hurtado-Chong A, Yusta-Boyo MJ, Vergaño-Vera E, Bulfone A, de Pablo F, Vicario-Abejón C. IGF-I promotes neuronal migration and positioning in the olfactory bulb and the exit of neuroblasts from the subventricular zone. Eur J Neurosci. 2009;30(5):742–55.PubMedCrossRef
85.
Oishi K, Watatani K, Itoh Y, Okano H, Guillemot F, Nakajima K, et al. Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1. Proc Natl Acad Sci USA. 2009;106(31):13064–9.PubMedCrossRefPubMedCentral
86.
Trejo JL, Llorens-Martín MV, Torres-Alemán I. The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol Cell Neurosci. 2008;37(2):402–11.PubMedCrossRef
87.
Madathil SK, Evans HN, Saatman KE. Temporal and regional changes in IGF-1/IGF-1R signaling in the mouse brain after traumatic brain injury. J Neurotrauma. 2010;27(1):95–107.PubMedCrossRef
88.
Sandberg Nordqvist AC, von Holst H, Holmin S, Sara VR, Bellander BM, Schalling M. Increase of insulin-like growth factor (IGF)-1, IGF binding protein-2 and -4 mRNAs following cerebral contusion. Brain Res Mol Brain Res. 1996;38(2):285–93.PubMedCrossRef
89.
Wang W, Li D, Li Q, Wang L, Bai G, Yang T, et al. Erythropoietin promotes peripheral nerve regeneration in rats by upregulating expression of insulin-like growth factor-1. Arch Med Sci. 2015;11(2):433–7.PubMedPubMedCentralCrossRef
90.
Isgaard J, Aberg D, Nilsson M. Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol. 2007;32(2):103–13.PubMed
91.
Corvin AP, Molinos I, Little G, Donohoe G, Gill M, Morris DW, et al. Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci Lett. 2012;520(1):51–6.PubMedCrossRef
92.
Llorens-Martín M, Torres-Alemán I, Trejo JL. Mechanisms mediating brain plasticity: IGF1 and adult hippocampal neurogenesis. Neuroscientist. 2009;15(2):134–48.PubMedCrossRef
93.
Tropea D, Kreiman G, Lyckman A, Mukherjee S, Yu H, Horng S, et al. Gene expression changes and molecular pathways mediating activity-dependent plasticity in visual cortex. Nat Neurosci. 2006;9(5):660–8.PubMedCrossRef
94.
Torres-Aleman I. Insulin-like growth factors as mediators of functional plasticity in the adult brain. Horm Metab Res. 1999;31(2–3):114–9.PubMedCrossRef
95.
96.
Bonfanti L. PSA-NCAM in mammalian structural plasticity and neurogenesis. Prog Neurobiol. 2006;80(3):129–64.PubMedCrossRef
97.
Monzo HJ, Park TIH, Dieriks BV, Jansson D, Faull RLM, Dragunow M, et al. Insulin and IGF1 modulate turnover of polysialylated neural cell adhesion molecule (PSA-NCAM) in a process involving specific extracellular matrix components. J Neurochem. 2013;126(6):758–70.PubMedCrossRef
98.
McCusker RH, McCrea K, Zunich S, Dantzer R, Broussard SR, Johnson RW, et al. Insulin-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocortical neurons. J Neuroimmunol. 2006;179(1–2):186–90.PubMedCrossRef
99.
Mendez P, Azcoitia I, Garcia-Segura LM. Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms. J Endocrinol. 2005;185(1):11–7.PubMedCrossRef
100.
Cardona-Gómez GP, Trejo JL, Fernandez AM, Garcia-Segura LM. Estrogen receptors and insulin-like growth factor-I receptors mediate estrogen-dependent synaptic plasticity. NeuroReport. 2000;11(8):1735–8.PubMedCrossRef
101.
Trejo JL, Carro E, Lopez-Lopez C, Torres-Aleman I. Role of serum insulin-like growth factor I in mammalian brain aging. Growth Horm IGF Res. 2004;14(Suppl A):S39–43.PubMedCrossRef
102.
Svensson J, Diez M, Engel J, Wass C, Tivesten A, Jansson J-O, et al. Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice. J Endocrinol. 2006;189(3):617–27.PubMedCrossRef
103.
Lupien SB, Bluhm EJ, Ishii DN. Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats. J Neurosci Res. 2003;74(4):512–23.PubMedCrossRef
104.
Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037(1–2):204–8.PubMedCrossRef
105.
Castro-Alamancos MA, Torres-Aleman I. Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide. Proc Natl Acad Sci USA. 1994;91(21):10203–7.PubMedCrossRefPubMedCentral
106.
Bluthé R-M, Kelley KW, Dantzer R. Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice. Brain Behav Immun. 2006;20(1):57–63.PubMedPubMedCentralCrossRef
107.
Ang LC, Bhaumick B, Juurlink BH. Neurite promoting activity of insulin, insulin-like growth factor I and nerve growth factor on spinal motoneurons is astrocyte dependent. Brain Res Dev Brain Res. 1993;74(1):83–8.PubMedCrossRef
108.
Pomerance M, Gavaret JM, Breton M, Pierre M. Effects of growth factors on phosphatidylinositol-3 kinase in astroglial cells. J Neurosci Res. 1995;40(6):737–46.PubMedCrossRef
109.
Zawada WM, Kirschman DL, Cohen JJ, Heidenreich KA, Freed CR. Growth factors rescue embryonic dopamine neurons from programmed cell death. Exp Neurol. 1996;140(1):60–7.PubMedCrossRef
110.
Masuda S, Chikuma M, Sasaki R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res. 1997;746(1–2):63–70.PubMedCrossRef
111.
Tranque P, Naftolin F, Robbins R. Differential regulation of astrocyte plasminogen activators by insulin-like growth factor-I and epidermal growth factor. Endocrinology. 1994;134(6):2606–13.PubMedCrossRef
112.
Bradshaw SL, Han VK. Hormonal regulation of astroglial insulin-like growth factor (IGF)-binding protein gene expression by IGFs and insulin. Endocrinology. 1993;133(4):1767–77.PubMedCrossRef
113.
Aberg ND, Blomstrand F, Aberg MAI, Björklund U, Carlsson B, Carlsson-Skwirut C, et al. Insulin-like growth factor-I increases astrocyte intercellular gap junctional communication and connexin43 expression in vitro. J Neurosci Res. 2003;74(1):12–22.PubMedCrossRef
114.
Suzuki K, Ikegaya Y, Matsuura S, Kanai Y, Endou H, Matsuki N. Transient upregulation of the glial glutamate transporter GLAST in response to fibroblast growth factor, insulin-like growth factor and epidermal growth factor in cultured astrocytes. J Cell Sci. 2001;114(Pt 20):3717–25.PubMed
115.
Sonnewald U, Wang AY, Petersen SB, Westergaard N, Schousboe A, Erikson R, et al. 13C NMR study of IGF-I- and insulin-effects on mitochondrial function in cultured brain cells. NeuroReport. 1995;6(6):878–80.PubMedCrossRef
116.
Dringen R, Hamprecht B. Glucose, insulin, and insulin-like growth factor I regulate the glycogen content of astroglia-rich primary cultures. J Neurochem. 1992;58(2):511–7.PubMedCrossRef
117.
Masters BA, Werner H, Roberts CT, LeRoith D, Raizada MK. Developmental regulation of insulin-like growth factor-I-stimulated glucose transporter in rat brain astrocytes. Endocrinology. 1991;128(5):2548–57.PubMedCrossRef
118.
Spina Purrello V, Cormaci G, Denaro L, Reale S, Costa A, Lalicata C, et al. Effect of growth factors on nuclear and mitochondrial ADP-ribosylation processes during astroglial cell development and aging in culture. Mech Ageing Dev. 2002;123(5):511–20.PubMedCrossRef
119.
Matsuda T, Murata Y, Kawamura N, Hayashi M, Tamada K, Takuma K, et al. Selective induction of alpha 1 isoform of (Na++K +)-ATPase by insulin/insulin-like growth factor-I in cultured rat astrocytes. Arch Biochem Biophys. 1993;307(1):175–82.PubMedCrossRef
120.
Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20(12):570–7.PubMedCrossRef
121.
Walter HJ, Berry M, Hill DJ, Logan A. Spatial and temporal changes in the insulin-like growth factor (IGF) axis indicate autocrine/paracrine actions of IGF-I within wounds of the rat brain. Endocrinology. 1997;138(7):3024–34.PubMedCrossRef
122.
Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer. 1992;50(2):215–22.PubMedCrossRef
123.
Lara-Diaz VJ, Castilla-Cortazar I, Martín-Estal I, García-Magariño M, Aguirre GA, Puche JE, et al. IGF-1 modulates gene expression of proteins involved in inflammation, cytoskeleton, and liver architecture. J Physiol Biochem. 2017;73:245–58.PubMedPubMedCentralCrossRef
124.
Morales-Garza LA, Puche JE, de la Garza RG, Muñoz-Morón Ú, Castilla-Cortázar I. Experimental approach to IGF-1 therapy in acute liver damage: acute injury by carbon tetrachloride in controls and mice with partial IGF-1 deficiency. J Hepatol. 2017;66(1):1–14.CrossRef
125.
LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. In: Endocrine reviews, vol. 16. 1995. p. 143–63.PubMedCrossRef
126.
Fernandez S, Fernandez AM, Lopez-Lopez C, Torres-Aleman I. Emerging roles of insulin-like growth factor-I in the adult brain. Growth Horm IGF Res. 2007;17(2):89–95.PubMedCrossRef
127.
García-Fernández M, Delgado G, Puche JE, González-Barón S, Castilla Cortázar I. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinology. 2008;149(5):2433–42.PubMedCrossRef
128.
Castilla-Cortazar I, Guerra L, Puche JE, Munoz U, Barhoum R, Escudero E, et al. An experimental model of partial insulin-like growth factor-1 deficiency in mice. J Physiol Biochem. 2013;70:129–39.PubMedCrossRef
129.
Puche JE, Muñoz Ú, García-Magariño M, Sádaba MC, Castilla-Cortázar I. Partial IGF-1 deficiency induces brain oxidative damage and edema, which are ameliorated by replacement therapy. Biofactors. 2016;42(1):60–79.PubMed
130.
Castilla-Cortázar I, Iturrieta I, García-Magariño M, Puche JE, Martín-Estal I, Aguirre GA, et al. Neurotrophic factors and their receptors are altered by the mere partial IGF-1 deficiency. Neuroscience. 2019;404:445–58.PubMedCrossRef
131.
Gasperi M, Castellano AE. Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases. J Endocrinol Investig. 2010;33(8):587–91.CrossRef
132.
Gubbi S, Quipildor GF, Barzilai N, Huffman DM, Milman S. 40 years of IGF1: IGF1: the Jekyll and Hyde of the aging brain. J Mol Endocrinol. 2018;61(1):T171–85.PubMedPubMedCentralCrossRef
133.
134.
Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T. Relationship between serum insulin-like growth factor-1 levels and Alzheimer’s disease and vascular dementia. J Am Geriatr Soc. 2005;53(10):1748–53.PubMedCrossRef
135.
Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentation of growth hormone—a new inborn error of metabolism? Isr J Med Sci. 1966;2(2):152–5.PubMed
136.
Laron Z. Short stature due to genetic defects affecting growth hormone activity. N Engl J Med. 1996;334(7):463–5.PubMedCrossRef
137.
Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 1995;8(3):149–58.PubMedCrossRef
138.
139.
Wu A, Grant DB, Hambley J, Levi AJ. Reduced serum somatomedin activity in patients with chronic liver disease. Clin Sci Mol Med. 1974;47(4):359–66.PubMed
140.
Picardi A, de Oliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortázar I, et al. Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol. 1997;26(1):191–202.PubMedCrossRef
141.
Pascual M, Castilla-Cortazar I, Urdaneta E, Quiroga J, Garcia M, Picardi A, et al. Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I. Am J Physiol Gastrointest Liver Physiol. 2000;279(2):G319–24.PubMedCrossRef
142.
Castilla-Cortázar I, Pascual M, Urdaneta E, Pardo J, Puche JE, Vivas B, et al. Jejunal microvilli atrophy and reduced nutrient transport in rats with advanced liver cirrhosis: improvement by Insulin-like Growth Factor I. BMC Gastroenterol. 2004;4:12.PubMedPubMedCentralCrossRef
143.
Castilla-Cortázar I, Picardi A, Tosar A, Ainzúa J, Urdaneta E, García M, et al. Effect of insulin-like growth factor I on in vivo intestinal absorption of d-galactose in cirrhotic rats. Am J Physiol. 1999;276(1 Pt 1):G37–42.PubMed
144.
Castilla-Cortazar I, Prieto J, Urdaneta E, Pascual M, Nuñez M, Zudaire E, et al. Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology. 1997;113(4):1180–7.PubMedCrossRef
145.
Cemborain A, Castilla-Cortázar I, García M, Quiroga J, Muguerza B, Picardi A, et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol. 1998;28(1):122–31.PubMedCrossRef
146.
Cemborain A, Castilla-Cortázar I, García M, Muguerza B, Delgado G, Díaz-Sánchez M, et al. Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem. 2000;56(2):91–9.PubMedCrossRef
147.
Castilla-Cortazar I, Quiroga J, Prieto J. Insulin-like growth factor-I, liver function, and hypogonadism in rats with experimentally induced cirrhosis. Hepatology. 2000;31(6):1379.PubMedCrossRef
148.
Castilla-Cortazar I, Garcia M, Quiroga J, Diez N, Diez-Caballero F, Calvo A, et al. Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology. 2000;31(3):592–600.PubMedCrossRef
149.
Castilla-Cortázar I, Aliaga-Montilla MA, Salvador J, García M, Delgado G, González-Barón S, Quiroga J, Prieto J. Insulin-like growth factor-I restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats. Liver. 2001;21:405–9.PubMedCrossRef
150.
Pérez R, García-Fernández M, Díaz-Sánchez M, Puche JE, Delgado G, Conchillo M, et al. Mitochondrial protection by low doses of insulin-like growth factor-I in experimental cirrhosis. World J Gastroenterol. 2008;14:2731–9.PubMedPubMedCentralCrossRef
151.
García-Fernández M, Castilla-Cortázar I, Díaz-Sanchez M, Navarro I, Puche JE, Castilla A, et al. Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis. BMC Gastroenterol. 2005;5:7.PubMedPubMedCentralCrossRef
152.
Muguerza B, Castilla-Cortázar I, García M, Quiroga J, Santidrián S, Prieto J. Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta. 2001;1536(2–3):185–95.PubMedCrossRef
153.
Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, et al. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology. 1997;113(5):1682–91.PubMedCrossRef
154.
Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero J-I, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol. 2005;43(4):630–6.PubMedCrossRef
155.
Ceda GP, Dall’Aglio E E, Maggio M, Lauretani F, Bandinelli S, Falzoi C, et al. Clinical implications of the reduced activity of the GH-IGF-I axis in older men. J Endocrinol Investig. 2005;28(11 Suppl Proceedings):96–100.
156.
Sun LY, Al-Regaiey K, Masternak MM, Wang J, Bartke A. Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol Aging. 2005;26(6):929–37.PubMedCrossRef
157.
Sonntag WE, Lynch CD, Cooney PT, Hutchins PM. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology. 1997;138(8):3515–20.PubMedCrossRef
158.
Sonntag WE, Carter CS, Ikeno Y, Ekenstedt K, Carlson CS, Loeser RF, et al. Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology. 2005;146(7):2920–32.PubMedCrossRef
159.
Shimokawa I, Higami Y, Tsuchiya T, Otani H, Komatsu T, Chiba T, et al. Life span extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction. FASEB J. 2003;17(9):1108–9.PubMedCrossRef
160.
161.
Sonntag WE, Bennett C, Ingram R, Donahue A, Ingraham J, Chen H, et al. Growth hormone and IGF-I modulate local cerebral glucose utilization and ATP levels in a model of adult-onset growth hormone deficiency. Am J Physiol Endocrinol Metab. 2006;291(3):E604–10.PubMedCrossRef
162.
Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Paolisso G, et al. Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. Am J Physiol Endocrinol Metab. 2007;292(1):E353–8.PubMedCrossRef
163.
Groban L, Pailes NA, Bennett CDL, Carter CS, Chappell MC, Kitzman DW, et al. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci. 2006;61(1):28–35.PubMedCrossRef
164.
Li Q, Wu S, Li S-Y, Lopez FL, Du M, Kajstura J, et al. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage. Am J Physiol Heart Circ Physiol. 2007;292(3):H1398–403.PubMedCrossRef
165.
166.
Tollet-Egnell P, Flores-Morales A, Odeberg J, Lundeberg J, Norstedt G. Differential cloning of growth hormone-regulated hepatic transcripts in the aged rat. Endocrinology. 2000;141(3):910–21.PubMedCrossRef
167.
Puche JE, García-Fernández M, Muntané J, Rioja J, González-Barón S, Cortazar IC. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology. 2008;149:2620–7.PubMedCrossRef
168.
García-Fernández M, Delgado G, Puche JE, González-Barón S, Cortázar IC. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinology. 2008;149:2433–42.PubMedCrossRef
169.
Pellecchia MT, Pivonello R, Salvatore E, Faggiano A, Barone P, De Michele G, et al. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson’s disease and idiopathic late-onset cerebellar ataxia. Clin Endocrinol. 2005;62(4):428–33.CrossRef
170.
Volpi R, Caffarra P, Scaglioni A, Boni S, Saginario A, Chiodera P, et al. Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson’s disease. Neuropsychobiology. 1997;35(2):79–83.PubMedCrossRef
171.
Bernhard FP, Heinzel S, Binder G, Weber K, Apel A, Roeben B, et al. Insulin-like growth factor 1 (IGF-1) in Parkinson’s disease: potential as trait-, progression- and prediction marker and confounding factors. PLoS ONE. 2016;11(3):e0150552.PubMedPubMedCentralCrossRef
172.
Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, et al. Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol. 2011;68(7):925–31.PubMedCrossRef
173.
Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(5):536–8.PubMedCrossRef
174.
Mashayekhi F, Mirzajani E, Naji M, Azari M. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease. J Clin Neurosci. 2010;17(5):623–7.PubMedCrossRef
175.
Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Park Relat Disord. 2014;20(2):212–6.CrossRef
176.
Fiszer U, Michałowska M, Baranowska B, Wolińska-Witort E, Jeske W, Jethon M, et al. Leptin and ghrelin concentrations and weight loss in Parkinson’s disease. Acta Neurol Scand. 2010;121(4):230–6.PubMedCrossRef
177.
Tuncel D, Inanc Tolun F, Toru I. Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson’s disease. Mediators Inflamm. 2009;2009:132464.PubMedPubMedCentralCrossRef
178.
Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson’s disease. Eur J Neurol. 2014;21(5):802–7.PubMedCrossRef
179.
Picillo M, Erro R, Santangelo G, Pivonello R, Longo K, Pivonello C, et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease. J Neurol. 2013;260(7):1724–30.PubMedCrossRef
180.
Picillo M, Pivonello R, Santangelo G, Pivonello C, Savastano R, Auriemma R, et al. Serum IGF-1 is associated with cognitive functions in early, drug-naive Parkinson’s disease. PLoS ONE. 2017;12(10):e0186508.PubMedPubMedCentralCrossRef
181.
Li D-H, He Y-C, Quinn TJ, Liu J. Serum insulin-like growth factor-1 in patients with de novo, drug naïve Parkinson’s disease: a meta-analysis. PLoS ONE. 2015;10(12):e0144755.PubMedPubMedCentralCrossRef
182.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302(5646):841.CrossRefPubMed
183.
Kumari U, Tan EK. LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J. 2009;276(22):6455–63.PubMedCrossRef
184.
Licker V, Kövari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinson’s disease research. J Proteomics. 2009;73(1):10–29.PubMedCrossRef
185.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.CrossRefPubMed
186.
Chung J-Y, Lee S-J, Lee S-H, Jung YS, Ha N-C, Seol W, et al. Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease. Neurosignals. 2011;19(2):86–96.PubMedCrossRef
187.
Kao S-Y. Rescue of α-synuclein cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun. 2009;385(3):434–8.PubMedCrossRef
188.
Kim W, Lee Y, McKenna ND, Yi M, Simunovic F, Wang Y, et al. miR-126 contributes to Parkinson’s disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol Aging. 2014;35(7):1712–21.PubMedPubMedCentralCrossRef
189.
Dulloo AG, Montani J-P. Obesity in Parkinson’s disease patients on electrotherapy: collateral damage, adiposity rebound or secular trends? Br J Nutr. 2005;93(4):417–9.PubMedCrossRef
190.
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson’s disease. Am J Epidemiol. 2004;159(6):547–55.PubMedCrossRef
191.
Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med. 2013;19(3):176–86.PubMedCrossRef
192.
Zaganas I, Kapetanaki S, Mastorodemos V, Kanavouras K, Colosio C, Wilks MF, et al. Linking pesticide exposure and dementia: what is the evidence? Toxicology. 2013;307:3–11.PubMedCrossRef
193.
Freire C, Koifman S. Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. Neurotoxicology. 2012;33(5):947–71.PubMedCrossRef
194.
Di Monte DA. The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003;2(9):531–8.PubMedCrossRef
195.
Aguirre GA, González-Guerra JL, Espinosa L, Castilla-Cortazar I. Insulin-like growth factor 1 in the cardiovascular system. In: Rev Physiol Biochem Pharmacol. 2018.
196.
Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson’s disease. Gene. 2013;532(1):18–23.PubMedCrossRef
Metadata
Title
Is insulin-like growth factor-1 involved in Parkinson’s disease development?
Authors
Inma Castilla-Cortázar
Gabriel A. Aguirre
Giovana Femat-Roldán
Irene Martín-Estal
Luis Espinosa
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2020
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-020-02223-0

Other articles of this Issue 1/2020

Journal of Translational Medicine 1/2020 Go to the issue

Letter to the Editor

Survival differences by ethnicity among patients diagnosed with bladder cancer

Research

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

Research

Upregulation of microRNA-328-3p by hepatitis B virus contributes to THLE-2 cell injury by downregulating FOXO4

Research

Identifying the pattern of immune related cells and genes in the peripheral blood of ischemic stroke

Correction

Correction to: Crystal structure of PKG Iβ holoenzyme reveals a trans‑inhibiting dimer assembly

Research

Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits